SCHEMBL1132334

SCHEMBL1132334

CNC(CO)CNCC(C)(C)c1ccccc1OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
NR3C2 P08235 1/20 0.32
ATM Q13315 1/20 0.32
CASR P41180 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KCNA5 P22460 2/20 0.32
HTR1A P08908 1/20 0.32
ADRA1D P25100 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132330 1.00 AGTR1 (0.35) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1132372 0.81 AGTR1 (0.37) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1132369 0.81 AGTR1 (0.37) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1132332 0.75 ALDH1A1 (0.38) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1132906 0.74 CYP2D6 (0.40) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1133037 0.72 LMNA (0.34) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1133034 0.72 LMNA (0.34) AGTR1LMNACYP1A2MEN1KMT2A
SCHEMBL1132788 0.70 CYP2D6 (0.44) AGTR1LMNACYP1A2CYP2D6CYP2C19
SCHEMBL1132790 0.70 CYP2D6 (0.44) AGTR1LMNACYP1A2CYP2D6CYP2C19
SCHEMBL24011236 0.69 MTNR1A (0.51) MEN1KMT2AGAAALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 AGTR1 4520/4885LMNA 1555/4885CYP1A2 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.